Components of the Signature Orthopaedics hip replacement range are intended to replace a hip joint where bone stock is sufficient to support the implant. When a surgeon has selected prosthetic replacement as the preferred treatment, the devices are indicated for:

Non-inflammatory degenerative joint disease including osteoarthritis or avascular necrosis
Inflammatory joint disease including rheumatoid arthritis
Correction of functional deformity including congenital hip dysplasia
Traumatic injury involving the hip joint including traumatic arthritis or femoral head or neck fracture
Failed previous hip surgery including internal fixation or joint fusion, reconstruction, hemiarthroplasty, surface replacement, or total replacement

Signature Orthopaedics' Origin, NEO-T, Remedy and Pegasus femoral stems, and Logical acetabular cups are intended for cementless fixation only. Signature Orthopaedics' Evolve femoral stems are intended for cemented fixation only.

Signature Orthopaedics' BiPolar Head is intended for hemi-hip arthroplasty only, where the natural acetabulum does not require replacement. The BiPolar Head is indicated for bone fractures or pathologies involving only the femoral head/neck and/or proximal femur, such as:

Acute femoral head or neck fracture
Fracture dislocation of the hip
Avascular necrosis of the femoral head
Non-union of femoral neck fractures
Certain high subcapital and femoral neck fractures in the elderly
Degenerative arthritis involving only the femoral head

Device Description

The Remedy™ and Pegasus™ hip stems are intended for cementless use in total hip arthroplasty. The Evolve™ hip stem is intended for cemented total hip arthroplasty. The Remedy™, Pegasus™ and Evolve™ hip stems connect to a femoral head (cobalt-chrome alloy or ceramic) via 12/14 taper connection.

The Remedy™ Hip Stem has a tapered wedge geometry. The stem is manufactured from titanium alloy per ASTM F136. The proximal stem is porous coated with titanium beads and particles per ASTM F67 and the distal stem is matte finished.

The Pegasus™ is a double tapered, straight stem with rectangular cross-section. The stem has a lateral wing for engaging the greater trochanter. The stem is manufactured from titanium alloy per ASTM F136. The stem is grit blasted below the resection line.

The Evolve™ Hip Stem is a highly polished, tapered wedge stem with a rounded crosssection. The Evolve™ Hip Stem is manufactured from high nitrogen stainless steel per ISO 5832-9. The Evolve™ Hip Stem is available in two variants, the Masters series and the Helios Series. Both variants share similar general geometry but are sized differently to provide a more complete range. The Evolve™ Hip Stem includes two accessories, the Evolve™ Distal Centralizer and Evolve™ Cement Plug. The Evolve™ Distal Centralizer is a PMMA cap that sits on the end of the Evolve™ Hip Stem and centralizes it within the femoral canal. The Evolve™ Cement Plug is manufactured from polyethylene per ASTM F648 and is pressed into the femoral canal prior to inserting the Evolve™ Hip Stem to allow cement pressurization.

The BiPolar Head consists of a stainless steel outer shell (per ISO5832-9) and a UHMWPE insert (per ASTM F648). The outer shell is highly polished to articulate against the patient's natural acetabulum. The insert articulates against a Signature Orthopaedics 28mm cobalt-chrome femoral head (K121297). The 28mm femoral head connects to a femoral stem from Signature Orthopaedics' range to complete the hip hemiarthroplasty.

AI/ML Overview

The provided text describes a 510(k) premarket notification for various hip implants (Remedy™, Pegasus™ and Evolve™ Hip Stems and BiPolar Head) and details the non-clinical performance testing conducted to support their substantial equivalence claim to predicate devices. It does not present acceptance criteria in a quantitative format, nor does it detail a clinical study with a control group or human readers.

Here's an analysis of the requested information based on the provided text:

1. A table of acceptance criteria and the reported device performance

The document does not explicitly state quantitative acceptance criteria in a table format. Instead, it lists general performance tests conducted and then concludes that "Non-clinical testing results support the substantial equivalence claim. The RemedyTM, Pegasus™ and Evolve™ Hip Stems and BiPolar Head are expected to perform adequately during clinical use."

The performance tests conducted include:

Acceptance Criteria (Implied)	Reported Device Performance
Adequate Range of Motion	Verified
Sufficient Component Connection Strength	Verified
Low Fretting Corrosion	Verified
Ceramic Head Burst Resistance	Verified
Femoral Stem Fatigue Resistance	Verified
Adequate Coating Characterization	Verified
Adequate Abrasion Resistance of Coating	Verified
Adequate Adhesion Strength of Coating	Verified
Sufficient BiPolar Head Disclamping Resistance	Verified

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

The document refers to "non-clinical testing and engineering evaluations." This implies in-vitro or bench testing, not patient data. Therefore, concepts like sample size, country of origin, or retrospective/prospective for a patient-based test set are not applicable here. The "test set" would consist of the orthopedic implants subjected to the various physical and mechanical tests. The sample sizes for each specific test are not reported. The company is Australia-based (Signature Orthopaedics Pty Ltd, Lane Cove, NSW 2066, Australia).

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

This question is not applicable. The device is a physical hip implant. "Ground truth" in this context would refer to the physical and mechanical properties of the device as measured by engineering standards, not expert interpretations of medical images or clinical outcomes.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

This question is not applicable as the evaluation involves non-clinical engineering tests, not human interpretation or adjudication of medical data.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

No, a multi-reader multi-case (MRMC) comparative effectiveness study was not done. This type of study is relevant for diagnostic devices that involve human interpretation of medical images, often with AI assistance. The document describes hip implants, which are surgical devices, and the testing performed is non-clinical engineering evaluation.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

No, a standalone algorithm performance study was not done. This question is also relevant for AI/software as a medical device (SaMD) and does not apply to physical hip implants.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

For this type of device, the "ground truth" for the non-clinical testing refers to established engineering standards, material properties, and biomechanical principles. For example, fatigue testing would compare the device's performance against known limits for medical implants, and material characterization would be compared against ASTM or ISO standards.

8. The sample size for the training set

This question is not applicable. There is no "training set" as this is not an AI/machine learning device. The "training" in this context would imply the manufacturing and design process of the device itself and the various components.

9. How the ground truth for the training set was established

This question is not applicable for the same reason as point 8. The "ground truth" for the design and manufacturing of the implants would be established through engineering specifications, material selection criteria based on ISO/ASTM standards, and biomechanical research for hip implant design.

Summary

{0}------------------------------------------------

، ﺗ

Signature Orthopaedics Pty Ltd

JUL 2 2 2014

2	510(K) SUMMARY
JUL 22 2014
	Manufacturer:	Signature Orthopaedics Pty Ltd7 Sirius RoadLane Cove, NSW 2066Australia
	Device Trade Name:	Remedy™™, Pegasus™ and Evolve™ Hip Stems and BiPolarHead
	Common Name:	Hip Prosthesis
	Contact:	Dr. Declan BrazilManaging Director
	Prepared By:	Signature Orthopaedics Pty Ltd7 Sirius RoadLane Cove, NSW 2066AustraliaPhone: +61 (2) 9428 5181Fax: +61 (2) 8456 6065
	Date Prepared:	October 30th, 2013
	Classification:	Class II per 21 CFR 888.3358: Hip joint metal/polymer/metalsemi-constrained porous-coated uncemented prosthesis (LPH)Class II per 21 CFR 888.3353: Hip joint metal/ceramic/polymersemi-constrained cemented or nonporous uncemented prosthesis(LZO)Class II per 21 CFR 888.3350: Hip joint metal/polymer semi-constrained cemented prosthesis (JDI)Class II per 21 CFR 888.3390: Hip joint femoral (hemi-hip)metal/polymer cemented or uncemented prosthesis (KWY)
	Predicate Devices:	Substantial equivalence to the following devices is claimed:• Signature Orthopaedics Origin Total Hip System(K121297)• DePuy Titanium Tri-Lock Hip Stem (K010367)• Smith & Nephew SL PLUS Standard and Lateral FemoralHip Stem (K072852)• Howmedica Exeter Hip Stem (K110290)

{1}------------------------------------------------

Signature Orthopaedics Pty Ltd

· Howmedica Exeter Distal Centralizer (K974054)
· Smith & Nephew Buck Cement Restrictor (K791125)
· DePuy Self-Centering Hip (K812672)
Medacta Bipolar Heads (K091967)

Device Description:

The Remedy™ and Pegasus™ hip stems are intended for cementless use in total hip arthroplasty. The Evolve™ hip stem is intended for cemented total hip arthoplasty. The Remedy™, Pegasus™ and Evolve™ hip stems connect to a femoral head (cobalt-chrome allov or ceramic) via 12/14 taper connection.

Indications for Use:

· Non-inflammatory degenerative joint disease including osteoarthritis or avascular necrosis
· Inflammatory joint disease including rheumatoid arthritis
· Correction of functional deformity including congenital hip dysplasia
· Traumatic injury involving the hip joint including traumatic arthritis or femoral head or neck fracture
· Failed previous hip surgery including internal fixation or joint fusion, reconstruction, hemiarthroplasty, surface replacement, or total replacement

{2}------------------------------------------------

Signature Orthopaedics Pty Ltd

. Acute femoral head or neck fracture
Fracture dislocation of the hip .
. Avascular necrosis of the femoral head
. Non-union of femoral neck fractures
. Certain high subcapital and femoral neck fractures in the elderly
. Degenerative arthritis involving only the femoral head

Performance Testing:

Non-clinical testing and engineering evaluations were conducted to verify that the performance of the Remedy™, Pegasus™ and Evolve™ Hip Stems and BiPolar Head are adequate for anticipated in-vivo use. Non-clinical testing included:

. Range of motion analysis
. Component connection strength and fretting corrosion testing
. Ceramic head burst testing
. Femoral stem fatigue testing
Various coating characterization, abrasion and adhesion strength testing ●
. BiPolar head disclamping resistance testing

Substantial Equivalence:

The Remedy™ Hip Stem's design is similar to the DePuy Titanium Tri-Lock Hip Stem (K010367) predicate device and the porous coating is identical to the Signature Orthopaedics Logical G-Series Acetabular Cup (K121297). The Pegasus™ Hip Stem's design is similar to the Smith & Nephew SL PLUS Hip Stem (K072852) and the Zimmer Zweymuller SL Hip Stem (K962101) predicate devices. The Evolve™ Hip Stem's design is similar to the Howmedica Exeter Hip Stem (K110290). The Evolve™ Hip Stem's distal centralizer and cement plug are similar to those of the Exeter stem, K974054 and K980843 respectively. The BiPolar Head's design is similar to the DePuy Self-Centering Hip (K812672) predicate device. The Remedy™, Pegasus™ and Evolve™ Hip Stems are identical to the Signature Orthopaedics Total Hip System (K121297) in terms of intended use, indications for use, modular connection design, material, sterilization and packaging. The BiPolar head also shares identical modular connection design, material, sterilization and packaging as the Signature Orthopaedics Total Hip System (K121297), but it is intended for use as part of a hip hemi-arthroplasty. Non-clinical testing results support the substantial equivalence claim. The RemedyTM, Pegasus™ and Evolve™ Hip Stems and BiPolar Head are expected to perform adequately during clinical use.

{3}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three lines representing its body and wings. The eagle is facing right. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular fashion around the eagle.

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

July 22, 2014

Signature Orthopedics Pty Ltd Dr. Declan Brazil Managing Director 7 Sirius Road Lane Cove. NSW 2066 Australia

Re: K133370

Trade/Device Name: Remedy™, Pegasus™ and Evolve™ Hip Stems and BiPolar Head Regulation Number: 21 CFR 888.3358 Regulation Name: Hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis Regulatory Class: Class II Product Code: LPH, LZO, JDI, KWY Dated: June 19, 2014 Received: June 26, 2014

Dear Dr. Brazil:

We have reviewed your Section 510(k) promarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21, Parts 800 to 898. In addition. FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA`s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21

{4}------------------------------------------------

Page 2 - Dr. Declan Brazil

CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours,

Lori A. Wiggins

for
Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

1 INDICATIONS FOR USE STATEMENT

510(k) Number (if Known): - K1333370

Device Name: Remedy™, Pegasus™ and Evolve™ Hip Stems and BiPolar Head

Indications For Use:

Components of the Signature Orthopsedies hip replacement range are intended to replace a hip joint where bone stock is sufficient to support the implant. When a surgen has selected prosibetic replacement as the preferred treatment, the devices are indicated for:

Non-inflammatory degenerative joint disease including osteoarthritis or avascular necrosis .
. Inflammatory joint disease including theumatoid arthritis
Correction of functional deformity including congenital hip dysplasia .
Traumatic injury involving the hip joint including traumatic arthritis or femoral head or neck fracture .
Failed previous hip surgery including internal fixation or joint fusion, reconstruction, hemiarthroplasty, surface replacement, or total replacement

Signature Orthopaedics' Origin, NEO-T, Remedy and Pegasus femoral stems, and Logical acetabular cups are intended for cementless fixation only. Signature Orthopactics' Evolve temoral stems are intended for cemented fixation only.

Signature Orthopactics' BiPolar Head is intended for hemi-hip arthroplasty only, where the natural acetabulum does not require replacement. The BiPotar Head is indicated for bone fractures or pathologies involving only the femoral headment and/or proximal femur, such as:

. Acute femoral head or neck fracture
. Fracture dislocation of the hip
. Avascular necrosis of the femoral head
. Non-union of femoral neck fractures
Certain high subcapital and femoral neck fractures in the elderly .
Degenerative arthritis involving only the femoral head .

Over-The-Counter Use: No Prescription Use: Yes AND/OR (Part 29 CFR 801 Subpart D) (Part 29 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Elizabeth南%rank -S

Division of Orthopedic Devices

Regulation Number and Section

§ 888.3358 Hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis.

(a)
Identification. A hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis is a device intended to be implanted to replace a hip joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across the joint. This generic type of device has a femoral component made of a cobalt-chromium-molybdenum (Co-Cr-Mo) alloy or a titanium-aluminum-vanadium (Ti-6Al-4V) alloy and an acetabular component composed of an ultra-high molecular weight polyethylene articulating bearing surface fixed in a metal shell made of Co-Cr-Mo or Ti-6Al-4V. The femoral stem and acetabular shell have a porous coating made of, in the case of Co-Cr-Mo substrates, beads of the same alloy, and in the case of Ti-6Al-4V substrates, fibers of commercially pure titanium or Ti-6Al-4V alloy. The porous coating has a volume porosity between 30 and 70 percent, an average pore size between 100 and 1,000 microns, interconnecting porosity, and a porous coating thickness between 500 and 1,500 microns. The generic type of device has a design to achieve biological fixation to bone without the use of bone cement.(b)
Classification. Class II.